TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16167910

Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethyl pyrrolidine (100 mg)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Ketoprofen (100 mg)
Number of subjects: 261
Study: 12859696

Group type: EXPERIMENTAL
Intervention: losartan (50 mg o.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 11130221

Group type: EXPERIMENTAL
Intervention: Intragastric enteral nutrition (EN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prokinetic agents (cisapride, erythromycin, metoclopramide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transpyloric migration of the feeding tube
Number of subjects: 0
Study: 9352040

Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference group (THA due to arthrosis)
Number of subjects: 20
Study: 8157039

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (AT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg (BFZ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined Atenolol 100 mg and Bendrofluazide 5 mg (AT/BFZ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 5 mg (Dz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3538476

Group type: EXPERIMENTAL
Intervention: Inhaled piriprost 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 12
Study: 31082749

Group type: EXPERIMENTAL
Intervention: Ginseng extract
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 28479294

Group type: EXPERIMENTAL
Intervention: Prototype novel tobacco vapor (PNTV) product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cigarette (CC1)
Number of subjects: 0
Study: 26179891

Group type: EXPERIMENTAL
Intervention: Dietary counseling and n-3 PUFA supplementation (2.4 g/d) for 36 months
Number of subjects: 563
Study: 23726602

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) after dose change
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) after dose change
Number of subjects: 110
Study: 21568751

Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 483
Study: 18582179

Group type: EXPERIMENTAL
Intervention: d-MPH-ER 20 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: d-MPH-ER 30 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: d,l-MPH-ER 36 mg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16861611

Group type: EXPERIMENTAL
Intervention: GHRP-2 low dose (0.1 microg/kg per hour)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GHRP-2 high dose (1 mug/kg per hour)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14561022

Group type: EXPERIMENTAL
Intervention: Acid suppressive therapy (AST)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (surgical and general internal medicine ward)
Number of subjects: 301
Study: 10746106

Group type: EXPERIMENTAL
Intervention: Sugar-rich cola
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sugar-free cola
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 11
Study: 8679353

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg body weight with lignocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 10 ml with lignocaine
Number of subjects: 60
Study: 1932606

Group type: EXPERIMENTAL
Intervention: Intravenous carbimide doses of 0.1, 0.3, 0.6, and 1 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral carbimide doses of 1 and 1.5 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral carbimide doses of 0.3 and 1 mg kg‐1
Number of subjects: 0
Study: 6410735

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium, iohexol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ionic contrast medium, sodium metrizoate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 60
Study: 30992235

Group type: EXPERIMENTAL
Intervention: CVT‐301 84 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa + CVT‐301
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carbidopa/levodopa + placebo
Number of subjects: 36
Study: 28824029

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 26361207

Group type: EXPERIMENTAL
Intervention: 450 IU FSH
Number of subjects: 356

Group type: COMPARATOR
Intervention: 600 IU FSH
Number of subjects: 356
Study: 24656524

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study: 23031071

Group type: EXPERIMENTAL
Intervention: 12-week physical activity and nutrition intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week maintenance program
Number of subjects: 0
Study: 19207292

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2550
Study: 18075285

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (10 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15379366

Group type: EXPERIMENTAL
Intervention: Imiquimod cream 5%
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study: 12142559

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with anti‐CD3‐expanded tumor vaccine draining lymph node lymphocytes (TVDLN) combined with systemic IL‐2 after vaccination with gene-modified autologous tumor cells.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gene-modified tumor cells expressing HLA-B7 and β2-microglobulin.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TVDLN lymphocytes activated and expanded ex vivo with anti‐CD3 and IL‐2.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lymph nodes harvested from patients.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MHC class I restricted, tumor‐specific cytokine secretion observed in lymphocytes.
Number of subjects: 20
Study: 9582132

Group type: EXPERIMENTAL
Intervention: Four layer compression bandaging in a leg ulcer clinic
Number of subjects: 233

Group type: COMPARATOR
Intervention: Usual care at home by the district nursing service
Number of subjects: 233
Study: 8610712

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms, nebulized, three times daily)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Albuterol (2.5 mg, nebulized, three times daily)
Number of subjects: 223
Study: 1707333

Group type: EXPERIMENTAL
Intervention: 1 mg b.i.d. of ketotifen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg b.i.d. of ketotifen
Number of subjects: 10
Study: 7192125

Group type: EXPERIMENTAL
Intervention: fenbufen (1000 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: acetylsalicylic acid (ASA) (3600 mg/d)
Number of subjects: 25
Study: 30427749

Group type: EXPERIMENTAL
Intervention: 15-valent pneumococcal conjugate vaccine (PCV15)
Number of subjects: 250

Group type: COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 250
Study: 27863323

Group type: EXPERIMENTAL
Intervention: Early-informed group (n=379)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Late-informed group (n=385)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Control group (n=379)
Number of subjects: 1143
Study: 26048851

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1278
Study: 23839541

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 6595
Study: 24567990

Group type: EXPERIMENTAL
Intervention: Mortality salience induction (experimental induction)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Mortality salience induction (experimental induction) with crime drama showing justice being carried out
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Induction to think about pain (control group)
Number of subjects: 1056
Study: 20308765

Group type: EXPERIMENTAL
Intervention: Zinc and multivitamin supplement (2mg/kg/day for 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Only multivitamin supplement
Number of subjects: 100
Study: 17653789

Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral formula (IEEF), n = 16
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular polymeric enteral formula (Control), n = 14
Number of subjects: 30
Study: 15831778

Group type: EXPERIMENTAL
Intervention: 12-mg HHER q24h
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-mg HHIR q6h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HHER
Number of subjects: 0
Study: 11981006

Group type: EXPERIMENTAL
Intervention: Mobilized peripheral-blood stem-cell transplantation (PBSCT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 93
Study: 10386509

Group type: EXPERIMENTAL
Intervention: Lean Red Meat (LRM)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Lean White Meat (LWM)
Number of subjects: 191
Study: 8919830

Group type: EXPERIMENTAL
Intervention: Low flow circuit (fresh gas flow 700 ml/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open system ventilation
Number of subjects: 50
Study: 2104806

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 37
Study: 332465

Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 1,000 MG/Trimethoprim (TM) 320 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sulfamethoxazole (SM) 1,600 mg/Trimethoprim 320 mg
Number of subjects: 198
Study: 31466505

Group type: EXPERIMENTAL
Intervention: Pattern/Audio‐Visual
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pattern/Visual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pattern-Goal/Visual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pattern-Goal/Audio-Visual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Visual-only
Number of subjects: 40
Study: 29135802

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Panretinal photocoagulation
Number of subjects: 120
Study: 29258499

Group type: EXPERIMENTAL
Intervention: SMS education intervention (daily messages and weekly reminders)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (traditional paper-based educational material)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SMS education intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 25951417

Group type: EXPERIMENTAL
Intervention: Laparoscopic esophageal myotomy (LEM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopic pneumatic dilatation (EPD)
Number of subjects: 50
Study: 23588319

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mirtazapine 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Driving performance (SD of lateral position)
Number of subjects: 24
Study: 21775558

Group type: EXPERIMENTAL
Intervention: Weight-loss intervention (n = 291; mean weight loss: 4.4 kg)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group (n = 294; mean weight loss: 0.8 kg)
Number of subjects: 585
Study: 19567093

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg once a week for 4 weeks, then 100 mg once a week for 8 weeks for HD subgroup; 200 mg once a week for 4 weeks, then 200 mg once every other week for 8 weeks for PD subgroup)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Oral medication (ferrous succinate 200 mg tid for 12 weeks)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (PD subgroup)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: EPO + intravenous iron sucrose
Number of subjects: 194
Study: 16734581

Group type: EXPERIMENTAL
Intervention: Two two‐piece implants placed in a non‐submerged procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two two‐piece implants placed in the traditional submerged procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two one‐piece dental implants placed in the traditional non‐submerged procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microgap at the crestal level in two‐piece implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (non-submerged, submerged, one-piece)
Number of subjects: 60
Study: 15229957

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly by subcutaneous injection
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 11718737

Group type: EXPERIMENTAL
Intervention: PC-Fix
Number of subjects: 896

Group type: COMPARATOR
Intervention: DCP
Number of subjects: 896
Study: 9150822

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine (n = 271)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: 100 mg maprotiline (n = 273)
Number of subjects: 544

Group type: COMPARATOR
Intervention: 40 mg paroxetine (n = 50)
Number of subjects: 544

Group type: COMPARATOR
Intervention: 150 mg maprotiline (n = 40)
Number of subjects: 544
Study: 8881802

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four to eight weeks (H pylori negative ulcers)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily plus amoxycillin 1 g twice daily for the first two weeks (H pylori positive ulcers)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Omeprazole alone for four to eight weeks while continuing NSAID therapy (H pylori positive ulcers)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: H pylori eradication
Number of subjects: 278

Group type: COMPARATOR
Intervention: Cumulative recurrence rates at six months
Number of subjects: 278
Study: 2805366

Group type: EXPERIMENTAL
Intervention: 2% aqueous lignocaine infiltrated into the nasal vestibule
Number of subjects: 26

Group type: COMPARATOR
Intervention: Topical anaesthesia of the nasal mucous membrane
Number of subjects: 26
Study: 1099859

Group type: EXPERIMENTAL
Intervention: oestradiolvalerate/norgestrel sequential therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 31169952

Group type: EXPERIMENTAL
Intervention: Spontaneous ovulation monitored by urinary luteinising hormone (LH)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Induced ovulation by administration of human chorionic gonadotrophin (hCG)
Number of subjects: 392
Study: 26970975

Group type: EXPERIMENTAL
Intervention: HSS-Group (closed-loop system for propofol administration)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group (manual administration of propofol)
Number of subjects: 150
Study: 26088663

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Community-intervention-as-usual (COM)
Number of subjects: 39
Study: 23574290

Group type: EXPERIMENTAL
Intervention: Self-relaxation training including progressive muscle relaxation and meditation based on sleep hygiene education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sleep hygiene education only
Number of subjects: 80
Study: 21542426

Group type: EXPERIMENTAL
Intervention: Herbal toothpaste (Sudantha)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 60
Study: 19339805

Group type: EXPERIMENTAL
Intervention: Guidelines group (ARIA guidelines with ebastine as oral antihistamine)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Free-choice treatment group
Number of subjects: 839
Study: 16764547

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Protein-enriched energy supplement
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191
Study: 15153734

Group type: EXPERIMENTAL
Intervention: Regimen A (3 instillations at 8-hourly intervals in 1 day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Regimen B (9 instillations at 8-hourly intervals in 3 days)
Number of subjects: 47
Study: 11421903

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily for 7 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 23
Study: 9416721

Group type: COMPARATOR
Intervention: No volume loading
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Volume loading of 15 ml/kg lactated Ringer's solution
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion of etilefrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study: 8495702

Group type: EXPERIMENTAL
Intervention: tetracycline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ampicillin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: trimethoprim/sulphamethoxazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo I
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo II
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: antibiotic (1 day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo (1 day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: antibiotic (3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo (3 days)
Number of subjects: 50
Study: 3352775

Group type: EXPERIMENTAL
Intervention: Total nodal irradiation (TNI)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP X 3-mantle irradiation-MOPP X 3; 3M)
Number of subjects: 257
Study: 31829432

Group type: EXPERIMENTAL
Intervention: Structural nested RMTL model (SNRMTLM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional intention-to-treat analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Per-protocol analysis
Number of subjects: 0
Study: 30035621

Group type: EXPERIMENTAL
Intervention: Vitamins and minerals supplementation
Number of subjects: 0
Study: 28724581

Group type: EXPERIMENTAL
Intervention: Triple-dose gadolinium administration during MRI scans
Number of subjects: 75
Study: 26142300

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Standard Dual-Chamber Pacing
Number of subjects: 605
Study: 22702228

Group type: EXPERIMENTAL
Intervention: Stopping smoking for 2 weeks
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Continuing to smoke for 2 weeks
Number of subjects: 1126
Study: 21981459

Group type: EXPERIMENTAL
Intervention: BFR walk group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 18720671

Group type: EXPERIMENTAL
Intervention: Formaldehyde ingestion
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study: 16582056

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT), 22 sessions
Number of subjects: 253

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 253
Study: 12655445

Group type: EXPERIMENTAL
Intervention: Hydration solution with 100 mEq/l sodium (regimen B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydration solution with 70 mEq/l sodium (regimen A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 30
Study: 11078293

Group type: EXPERIMENTAL
Intervention: Electron Beam Computed Tomography (EBCT)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Exercise Treadmill Testing (ETT)
Number of subjects: 207
Study: 8975683

Group type: EXPERIMENTAL
Intervention: Heightened awareness of theological beliefs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthropomorphic God concept
Number of subjects: 0
Study: 1596307

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6726650

Group type: EXPERIMENTAL
Intervention: Methadone (0.5, 1.0, or 2.0 times their regular maintenance dose of 40-60 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dextromethorphan (placebo control)
Number of subjects: 5
Study: 30816244

Group type: EXPERIMENTAL
Intervention: One night of total sleep deprivation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Fourth night with 8-9 hours in bed (control)
Number of subjects: 183
Study: 29489895

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 24
Study: 27009101

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNPs) injected into the subserosa of the stomach around the tumor before gastrectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no coloring material)
Number of subjects: 30
Study: 24263660

Group type: EXPERIMENTAL
Intervention: with mouthpiece (MP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: without mouthpiece (noMP)
Number of subjects: 21
Study: 23273042

Group type: EXPERIMENTAL
Intervention: Deprexis web-based psychological treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 80
Study: 20464803

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 17980884

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of ezetimibe and simvastatin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 16226024

Group type: EXPERIMENTAL
Intervention: Formoterol via Easyhaler
Number of subjects: 33

Group type: COMPARATOR
Intervention: Formoterol via Aerolizer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Spirometry (both devices)
Number of subjects: 33